Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Jurnal Riset Kesehatan Poltekkes Depkes Bandung Jurnal Penyakit Dalam Indonesia
Putri, Derby Ayudhia Utami Iskandar
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
KARAKTERISTIK DAN TATALAKSANA SINDROM EPILEPSI: SEBUAH TINJAUAN LITERATUR Putri, Derby Ayudhia Utami Iskandar; Sari, Riri Gusnita
JURNAL RISET KESEHATAN POLTEKKES DEPKES BANDUNG, Online ISSN 2579-8103 Vol 16 No 1 (2024): Jurnal Riset Kesehatan Poltekkes Depkes Bandung
Publisher : Poltekkes Kemenkes Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.34011/juriskesbdg.v16i1.2525

Abstract

Definisi dan klasifikasi sindrom epilepsi pertama kali disampaikan oleh International League Against Epilepsy (ILAE) tahun 1985. Menurut ILAE sindrom epilepsi merupakan gangguan epilepsi yang ditandai dengan sekelompok tanda dan gejala, yang dapat terjadi bersamaan. Gejala bergantung pada usia dan serangkaian penyakit penyerta tertentu.  Penulis bertujuan menggabungkan berbagai literatur terkini mengenai sindrom epilepsi. Literatur diambil menggunakan database Google Scholar, PubMed, Cochrane Library dalam kurun waktu 4 (empat) tahun, 2019-2023. Studi yang diikutsertakan ke dalam literatur yang sesuai dengan kriteria inklusi meliputi studi yang menjelaskan mengenai sindrom epilepsi dan karakteristiknya. Klasifikasi sindrom epilepsi dibagi berdasarkan jenis kejang dan onset usia. Setiap jenis memiliki karakteristik dan tatalaksana yang berbeda. Sindrom epilepsi pada masa anak yang paling sering dijumpai meliputi, Generalized Tonic-Clonic Seizures Alone/ GTCSA, Childhood Absence Epilepsy/ CAE, Lennox-Gastaut Syndrome/ LGS, West syndrome/ WS, Self-Limited Childhood Epilepsy with Centrotemporal Spikes/ SLCECTS. Dapat disimpulkan bahwa inisiasi pengobatan antikejang pada sindrom epilepsi bergantung pada usia dan efektivitas yang berbeda dari obat antiepilepsi.  
Laporan Kasus Hipokalemi Periodik Paralisis pada Pasien dengan Graves’ Disease Sirait, Anggi Cahaya Millenia S; Buharman, Borries Foresto; Putri, Adinda Zhafira Dyanti; Putri, Derby Ayudhia Utami Iskandar
Jurnal Penyakit Dalam Indonesia
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hypokalemia periodic paralysis (HPP) characterized by episodes of flaccid weakness or paralysis that may be associated with abnormalities of the serum potassium level. HPP often associated with hyperthyroidism and Graves’ disease. HPP prevalence is 1 in 100.000. Each individual has different clinical manifestations, so it’s necessary to adjust therapy based on the etiology. This case report was developed to provide more information regarding Graves’ disease, considering lack of information about management and description of HPP with Graves’ disease. A 27-year-old male with sudden weakness in both legs radiating to upper extremity, shortness of breath, palpitations, and sweating. Over the last 2 months, the patient’s weight has dropped drastically even though his appetite was increased. There were no complaints of nausea, vomiting, or increased frequency of defecation and urination. Previously, the patient had the similar experiences and received potassium transfusion twice. The patients revealed tachycardia, diffuse thyroid gland, fine hand tremor, superior motor streght 222/222 and inferior 111/111, hypokalemia (1.40 mmol/L), T4 total 197.80 nmol/L, and fluorescence T4 >320 m/U/mL. Graves’ disease that has become thyrotoxicosis can be accompanied by a picture of HPP or also called thyrotoxicosis periodic paralysis (TPP). Hypokalemia in TPP are not caused by potassium loss but due to intracellular potassium movement, so there’s a high possibility to hyperkalemia rebound. Treatment of TTP due to Grave’s disease is to prevent potassium transfer by administering beta blocker, potassium replacement, and treating hyperthyroidism.
Co-Authors Buharman, Borries Foresto Putri, Adinda Zhafira Dyanti Sari, Riri Gusnita Sirait, Anggi Cahaya Millenia S